Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for Fibromyalgia Management Axsome Therapeutics, Inc. a biopharmaceutical company pioneering innovative treatments for central nervous system (CNS) disorders, announced today that the first patient has been dosed in the FORWARD Phase…
Orion Revamps Packaging to Boost Patient Experience and Sustainability Since 2020, Orion has been systematically reimagining its product packaging with a dual focus on patient safety and environmental sustainability. This ongoing effort has touched every stage of the supply chain—from…
Sobi Exceeds 2025 Revenue and Adjusted EBITA Margin Outlook Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) today announced that its full-year 2025 revenue and adjusted EBITA margin have surpassed the company’s previous outlook, reflecting strong performance across its portfolio. Full-year…
Ipsen today announced the presentation of 14 scientific abstracts across a broad range of neurological conditions at TOXINS 2026, taking place from 14–17 January 2026 in Madrid. The presentations underscore Ipsen’s continued commitment to advancing evidence-based solutions and addressing persistent…
BridgeBio Pharma, Inc., a biopharmaceutical company focused on developing treatments for genetic diseases, announced plans to advance its long-term balance sheet strategy through a significant new financing initiative. The company disclosed that it intends to offer $550 million in aggregate…
Celltrion delivered a comprehensive update on its long-term growth strategy and next-generation therapeutic portfolio during the 44th Annual J.P. Morgan Healthcare Conference held in San Francisco, California. The global biopharmaceutical leader outlined major advances across its innovative drug pipeline—including antibody-drug…
Sandoz Secures European Commission Approval for Ondibta® (Insulin Glargine), Reinforcing Leadership in Biosimilars and Diabetes Care Sandoz a global leader in affordable medicines, today announced that the European Commission has granted marketing authorization for Ondibta® (insulin glargine), a solution for…
Teva Pharmaceuticals Highlights AJOVY® Efficacy in Pediatric Migraine Following Publication in New England Journal of Medicine Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today that the New England Journal of Medicine (NEJM)…
Galderma to Showcase Advanced Neuromodulator Data at TOXINS 2026 Galderma is set to reinforce its position as a global leader in injectable aesthetics with the presentation of new clinical and scientific data from its industry-leading neuromodulator portfolio at the TOXINS…
argenx SE a global immunology company focused on transforming outcomes for patients with severe autoimmune diseases, has announced a significant regulatory milestone for its flagship therapy, VYVGART® (IV: efgartigimod alfa-fcab). The U.S. Food and Drug Administration (FDA) has accepted the…